RP-323 is under clinical development by PhorMed and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RP-323’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-323 (TPA) is under development for the treatment of acute myelocytic leukemia (AML) in refractory patients, Hodgkin’s lymphoma, Parkinson's disease, stroke, COVID-19 associated acute respiratory distress syndrome (ARDS) and unspecified indication. It is administered through intravenous route. The drug candidate is 12-O-tetradecanoylphorbol-13-acetate which is a naturally occurring compound. It acts by targeting protein kinase C. It was also under development for the treatment of chronic myelocytic leukemia (CML, chronic myeloid leukemia), acute leukemia, non-Hodgkin lymphoma, aplastic anemia, chronic lymphocytic leukemia (CLL), myeloproliferative disorders and multiple myeloma (Kahler's disease) and myelodysplastic syndrome (MDS).
PhorMed is a clinical stage biopharmaceutical company developing RP-323, a gene repair therapy. PhorMed is headquartered in Beverly Hills, California, the US.
For a complete picture of RP-323’s drug-specific PTSR and LoA scores, buy the report here.